share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K：重大事件
美股SEC公告 ·  09/07 04:22

Moomoo AI 已提取核心信息

Aditxt, Inc., a biotech company, has announced amendments to its merger agreement with Evofem Biosciences, Inc. through a Current Report on Form 8-K filed with the SEC. The report, dated September 6, 2024, details the company's entry into Amendment No. 2 to the Amended and Restated Merger Agreement. This amendment adjusts the dates and amounts of the third and fourth equity investments Aditxt is making in Evofem. The third investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. The fourth investment date has been extended from September 30, 2024, to October 31, 2024, with the amount increased from $1 million to $1.5 million. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report also includes a cautionary note on forward-looking statements and clarifies that this is not an offer to sell securities or a solicitation of an offer to buy any securities.
Aditxt, Inc., a biotech company, has announced amendments to its merger agreement with Evofem Biosciences, Inc. through a Current Report on Form 8-K filed with the SEC. The report, dated September 6, 2024, details the company's entry into Amendment No. 2 to the Amended and Restated Merger Agreement. This amendment adjusts the dates and amounts of the third and fourth equity investments Aditxt is making in Evofem. The third investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. The fourth investment date has been extended from September 30, 2024, to October 31, 2024, with the amount increased from $1 million to $1.5 million. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report also includes a cautionary note on forward-looking statements and clarifies that this is not an offer to sell securities or a solicitation of an offer to buy any securities.
Aditxt公司，一家生物技术公司，已经通过提交给美国证券交易委员会的8-k表格对其与evofem biosciences公司的并购协议进行了修订。该报告日期为2024年9月6日，详细说明了该公司与修订的并购协议第二次修正案之间的关系。该修正案调整了aditxt在evofem中进行的第三和第四次股权投资的日期和金额。第三次投资日期由2024年9月6日更改为2024年9月30日，投资金额由200万美元减少至150万美元。第四次投资日期已从2024年9月30日延长至2024年10月31日，金额由100万美元增加至150万美元。合并将导致evofem成为aditxt的全资子公司。该报告还包括关于前瞻性声明的警示说明，并澄清这不是出售证券的要约或购买任何证券的邀请。
Aditxt公司，一家生物技术公司，已经通过提交给美国证券交易委员会的8-k表格对其与evofem biosciences公司的并购协议进行了修订。该报告日期为2024年9月6日，详细说明了该公司与修订的并购协议第二次修正案之间的关系。该修正案调整了aditxt在evofem中进行的第三和第四次股权投资的日期和金额。第三次投资日期由2024年9月6日更改为2024年9月30日，投资金额由200万美元减少至150万美元。第四次投资日期已从2024年9月30日延长至2024年10月31日，金额由100万美元增加至150万美元。合并将导致evofem成为aditxt的全资子公司。该报告还包括关于前瞻性声明的警示说明，并澄清这不是出售证券的要约或购买任何证券的邀请。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间